Welcome to our dedicated page for CIBUS SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cibus, Inc.'s SEC filings document an agricultural biotechnology company that uses proprietary gene-editing technologies to develop plant traits for licensing to seed companies. The filings describe its royalty-oriented model, productivity traits for major agricultural food crops, and trait categories tied to weeds, pests, diseases, sustainability and yield challenges.
The company's regulatory record includes 8-K material-event reports, financial-results exhibits, proxy materials, governance disclosures and capital-structure information for its Class A common stock. These filings also cover board appointments, compensatory arrangements, shareholder voting matters, material agreements, registered securities and business disclosures related to the development and commercialization of gene-edited crop traits.
Cibus, Inc. director Mark Terrence Finn reported receiving a grant of stock options. He was awarded 77,586 options to buy Class A common stock at an exercise price of $1.39 per share. The options vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or the company’s next annual shareholder meeting, subject to his continued service. The options expire on June 2, 2036, and were granted as compensation rather than through any open-market transaction.
Cibus, Inc. director August J. Moretti received a grant of 77,586 stock options on June 2, 2026 to buy Class A Common Stock at an exercise price of $1.39 per share. The options vest in full after one year or at the next annual shareholder meeting and expire on June 2, 2036.
Cibus, Inc. director Rory B. Riggs reported receiving a grant of stock options. The award covers 77,586 options to buy Class A common stock at an exercise price of $1.39 per share, expiring on June 2, 2036.
According to the terms, these options vest in full, subject to his continued service, on the earlier of the first anniversary of the June 2, 2026 grant date or the company’s next annual meeting of shareholders. Following this grant, Riggs holds 77,586 derivative securities directly.
Cibus, Inc. director Gerhard Prante reported an equity compensation grant involving the company’s Class A common stock. He acquired 64,748 shares at a stated price of $0.00 per share as a grant or award, rather than an open-market purchase. Following this award, his directly held position increased to 104,945 shares of Class A common stock.
The footnote explains that these are Restricted Stock Units that vest in full, subject to his continued service as a director, on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. This shows the grant is tied to ongoing board service rather than a discretionary market transaction.
Lehmann Jean-Pierre Jules reported acquisition or exercise transactions in this Form 4 filing.
Cibus, Inc. director Jean-Pierre Jules Lehmann received an award of 64,748 shares of Class A Common Stock in the form of Restricted Stock Units. The award carries a price of $0.00 per share, indicating equity compensation rather than a market purchase. Following this grant, Lehmann directly holds 763,904 shares. The RSUs vest in full, subject to his continued service, on the earlier of one year from the grant date or the company’s next annual meeting of shareholders.
Cibus, Inc. director Kimberly Ann Box received a grant of stock options on Class A Common Stock. The award covers 77,586 options with an exercise price of $1.39 per share and no upfront purchase cost. These options vest in full, subject to her continued service, on the earlier of the first anniversary of the June 2, 2026 grant date or the company’s next annual shareholder meeting, and expire on June 2, 2036. Following this grant, she holds 77,586 derivative securities directly through this option award.
Cibus, Inc. director Craig Wichner received a grant of stock options covering 77,586 shares of Class A common stock. The options have an exercise price of $1.39 per share and expire on June 2, 2036.
According to the award terms, the options vest in full if the director continues to serve until the earlier of the first anniversary of the grant date or the company’s next annual meeting of shareholders. After this grant, Wichner holds 77,586 derivative securities tied to the company’s stock, reflecting routine equity-based director compensation rather than an open-market purchase or sale.
Urban Thomas reported acquisition or exercise transactions in this Form 4 filing.
Cibus, Inc. director Urban Thomas received an equity award of 64,748 shares of Class A Common Stock at no purchase price, as reflected in a Form 4 insider filing. The award is in the form of Restricted Stock Units that vest in full, subject to his continued service, on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. Following this grant, Thomas is reported as directly holding 64,748 shares.
Cibus, Inc. is registering 10,738,040 shares of Class A Common Stock issuable upon exercise of outstanding warrants.
This prospectus covers the issuance of those shares upon warrant exercise and states that the Company will receive proceeds from such exercises. The prospectus discloses assumed share counts of 76,345,736 shares outstanding as of March 31, 2026 and presents dilution and tax-related information, including a net tangible book value (deficit) of $(228.3) million, or $(2.99) per share as of March 31, 2026. The Company states it intends to use net proceeds, if any, for working capital and to fund development of its Rice weed management traits.